Abstract

Swertiamarin is a lead, biologically active compound obtained from Enicostemma littorale Blume and known to be identified for the anti-diabetic activity. Present work comprises the synthesis and structural optimization of seven novel swertiamarin analogues and those were not being reported elsewhere till date. Swertiamarin was isolated, followed by modifications that have been accomplished amidst fluorinating, acetylating and oxidizing agents and also performed chromatographic purity and characterization of analogues. Furthermore, the swertiamarin analogues were screened for dipeptidyl peptidase IV (DPP-IV) enzyme inhibition with in silico studies. Besides, the pharmacokinetics and toxicity of analogues were predicted using ADMET software. In a nutshell, the compounds such as SNIPERSV-4 and SNIPERSV-7 have to pose good initial activity (∼48%) in comparison to standard DPP-IV inhibitor (Sitagliptin). The identified analogues were active against DPP-IV enzyme in preliminary screenings, and these findings would be beneficial for the new age researchers also for the therapy of diabetes.

摘要

Swertiamarin 是一种从Enicostemma littorale Blume获得的具有生物活性的铅化合物，已知具有抗糖尿病活性。目前的工作包括七种新的獐牙菜苷类似物的合成和结构优化，迄今为止尚未在其他地方报道。獐牙菜被分离出来，然后在氟化剂、乙酰化剂和氧化剂中进行了修饰，还进行了类似物的色谱纯度和表征。此外，用计算机筛选了獐牙菜苷类似物的二肽基肽酶 IV (DPP-IV) 酶抑制作用。学习。此外，使用ADMET软件预测了类似物的药代动力学和毒性。简而言之，与标准 DPP-IV 抑制剂（西格列汀）相比，SNIPERSV-4 和 SNIPERSV-7 等化合物必须具有良好的初始活性（~48%）。所鉴定的类似物在初步筛选中对 DPP-IV 酶具有活性，这些发现对新时代的研究人员也有益于糖尿病的治疗。